Evidence that cAMP plays a major role in cystogenesis has accumulated in recent years (1). cAMP stimulates cyst formation by promoting chloride-driven fluid secretion. Recent in vitro studies suggested that cAMP also stimulates B-Raf/ERK activation and proliferation of cyst-derived cells in a Ca^{2+}-inhibitable and Ras-dependent manner (2). The increased cAMP levels in polycystic kidneys (3–5), the origin of autosomal recessive (ARPKD) and dominant polycystic kidney disease (ADPKD) cysts predominantly from collecting ducts (6), and the V2 receptor-mediated vasopressin effect on adenylyl cyclase in principal cells (7) provided the rationale for treating PKD with vasopressin V2 receptor (VPV2) antagonists (4,5,8). The administration of the VPV2 antagonist OPC-31260 was shown to lower renal cAMP and inhibit disease development and progression in models orthologous to human cystic diseases. Here it is shown that OPC-41061, an antagonist chosen for its potency and selectivity for human VPV2, is effective in PCK rats. PCK kidneys have increased Ras-GTP and phosphorylated ERK levels and 95-kD/68-kD B-Raf ratios, changes that are corrected by the administration of OPC-31260 or OPC-41061. These results support the importance of cAMP in the pathogenesis of polycystic kidney disease, confirm the effectiveness of a VPV2 antagonist to be used in clinical trials for this disease, and suggest that OPC-31260 and OPC-41061 inhibit Ras/mitogen-activated protein kinase signaling in polycystic kidneys.

Effectiveness of Vasopressin V2 Receptor Antagonists OPC-31260 and OPC-41061 on Polycystic Kidney Disease Development in the PCK Rat

Xiaofang Wang,* Vincent Gattone II,† Peter C. Harris,* and Vicente E. Torres*

*Mayo Foundation, Rochester, Minnesota; and †Indiana University School of Medicine, Indianapolis, Indiana

Copyright © 2005 by the American Society of Nephrology

Published online ahead of print. Publication date available at www.jasn.org.

Address correspondence to: Dr. Vicente E. Torres, Division of Nephrology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. Phone: 507-284-7572; Fax: 507-266-9315; E-mail: torres.vicente@mayo.edu
Figure 1. Effect of OPC-41061 treatment at the specified concentrations on the development of polycystic kidney disease, urine output, and renal cAMP concentration in PCK rats ($n = 80;10$ rats per treatment and gender group). Data are expressed as means ± SD. Two-way ANOVA was used to determine gender and OPC-41061 effects. Correlations between renal cAMP concentrations and kidney weights or cyst volumes at killing in male and female animals.
were counted. The mitotic and apoptotic indices were calculated as the percentage of cells positive for proliferating cell nuclear antigen or the transferase-mediated dUTP nick-end labeling assay.

cAMP Content of Whole Kidneys
The kidneys were ground to fine powder under liquid nitrogen in a stainless steel mortar and homogenized in 10 volumes of cold 5% TCA in a glass-Teflon tissue grinder. After centrifugation at 600 \( \times \) g for 10 min, the supernatants were extracted with 3 volumes of water-saturated ether. After the aqueous extracts were dried, the reconstituted samples were processed without acetylation using an enzyme immunoassay kit (Sigma-Aldrich, St. Louis MO). The results were expressed in pmol/mg of protein (3).

Western Blot Analysis and Affinity Assay for Ras Activation
Total Ras, total ERK1/2, phosphorylated ERK1/2, and B-Raf were measured by Western blot analysis using anti-Ras (F132), -ERK1/2 (C16), -phosphorylated ERK1/2 (E4), and –B-Raf (C19) antibodies (Santa Cruz Biotechnology). The EZ-Detect Ras activation kit (Pierce Biotechnology, Rockford, IL) was used to measure Ras activation. This method uses a GST-fusion protein that contains the Ras-binding domain of Raf1 to specifically pull down active Ras. The pulled-down active Ras was detected by Western blot analysis using an anti-Ras antibody.

Statistical Analyses
Comparisons between groups were made using one-way or two-way ANOVA with least significant difference comparisons of the means or \( t \) test as appropriate. Data are expressed as means ± SD.

Results and Discussion
The PCK rat is a model of human ARPKD caused by a splicing mutation (IVS35–2A→T) that leads to a frameshift in the ortholog \( Pkhd1 \) as a result of skipping of exon 36 (10). This model is characterized by progressive cystogenesis and impairment of renal function. It exhibits a urine concentration defect, despite increased renal levels of cAMP and expression of aquaporin-2 and the VPV2. We previously showed that OPC-31260
administration markedly reduces the renal accumulation of cAMP and inhibits disease development and progression (4). Similar observations have been made in three additional models of PKD, the Pkd2<sup>WS25/−</sup> mouse (orthologous to human ADPKD), the pcy mouse (orthologous to human adolescent nephronophthisis), and the cpk mouse (a model of rapidly

Figure 3. Total and GTP-bound Ras, total and phosphorylated ERK1/2, and 95- and 68-kD B-Raf levels in PCK rats that were treated with 0.05% (n = 4) or 0.1% (n = 4) OPC-31260 compared with untreated control animals (n = 4) (A) or with 0.1% OPC-41061 (n = 6) compared with untreated control animals (n = 6) (B). OPC-31260 and OPC-41061 caused inhibition of Ras and ERK1/2 signaling and a reduction in 95-kD B-Raf relative to 68-kD B-Raf levels.
progressive ARPKD without a known human homologue) (4,5,7).

The potency and selectivity of vasopressin receptor antagonists is species dependent and varies between humans and rodents. OPC-41061 was developed through a series of structural conversions of OPC-31260 and selected for use in clinical trials because it is a more potent and selective human VPV2 antagonist than OPC-31260 (11). Despite the similarities between OPC-31260 and OPC-41061 in regards to chemical structure and mechanism of action, experiments were needed to confirm that OPC-41061 is also capable of inhibiting the development of PKD. Here we show that the administration of OPC-41061 between 3 and 10 wk of age lowers renal CAMP and exerts a protective effect on the development of PKD in PCK rats. This is reflected by significantly lower kidney weights, cyst and fibrosis volumes, and mitotic and apoptotic indices (Figure 1). Plasma blood urea nitrogen levels were normal and not significantly different between the groups. A statistically significant positive correlation was detected between the tissue levels of cAMP and the severity of PKD (Figure 1), consistent with a causal relationship between the two. Most of the protective effect of OPC-41061 was detectable with the lowest dose used in the study, a dose that caused only modest aquarexia. Limited additional protection was achieved by a 10-fold increase in the dose. Possibly, antagonism for the vasopressin V1a receptor and inhibition of intracellular calcium release at high concentrations of OPC-41061 may limit the potential benefit of higher doses of this compound (12). The administration of OPC-41061 was well tolerated, and no significant effect on plasma sodium was detected. Systolic BP were similar in the control (male, 124 ± 4; female, 125 ± 4 mmHg) and treated (male, 126 ± 3, 125 ± 3, 126 ± 3; female, 122 ± 4, 125 ± 3, 125 ± 4 mmHg) rats. As previously observed with OPC-31260, the administration of OPC-41061 did not inhibit the development of fibroproliferative liver disease, consistent with the absence of VPV2 in the liver.

A recent study showed that prolonged (at least 3 h) incubation of principal cells in a low-calcium medium or in the presence of calcium channel blockers allows cAMP activation of a B-Raf/ERK pathway and stimulation of cell proliferation in a PKA-, Src-, and Ras-dependent manner (2). The effect of calcium restriction was thought to be due to PI3K and Akt inhibition (replicated by PI3K or Akt inhibitors). Prolonged calcium restriction was deemed necessary to increase B-Raf levels (via adjustments in the synthesis and/or turnover rate). Because transfection of principal cells with a dominant negative polycystin-1 C-tail construct induced cAMP-dependent B-Raf and ERK activation, inhibitable by a calcium ionophore, the authors concluded that the proliferative cellular phenotype of PKD is linked directly to abnormalities in intracellular calcium homeostasis.

To determine whether these mechanisms described in vitro are operational in vivo, we measured Ras and ERK activation and B-Raf levels in kidneys from wild-type Sprague-Dawley and PCK rats. We found increased levels of Ras-GTP and phosphorylated ERK in the polycystic compared with the control kidneys (Figure 2). Total Ras and ERK were similar. Contrary to observations in cultured cells, we did not find increased levels of B-Raf in vivo. However, the ratio of the 95- and 62-kD B-Raf isoforms was somewhat higher in the PCK kidneys. This is consistent with recent reports indicating that the effect of cAMP on ERK activation and cell proliferation depends on the relative expression of these two splicing variants (95 and 62 kD) (13,14). cAMP stimulates cell proliferation in cells that express mostly the 95-kD isoform, whereas it is inhibitory in cells that do not express B-Raf or express mostly the 62-kD isoform. The relative expression of these two isoforms depends not only on cell type but also on cellular density (predominantly 95-kD isoform in subconfluent cells and 62-kD isoform in confluent cells) and may work as a molecular switch to activate and inhibit ERK and cell proliferation (15).

To determine whether the protective effects of OPC-31260 and OPC-41061 could be mediated, at least in part, by the inhibition of this Ras/B-Raf/ERK pathway, we measured the expression pattern and activation of Ras, B-Raf, and ERK in control and treated animals. Both compounds caused a significant inhibition of Ras and ERK, without affecting the total protein levels (Figure 3). These changes were accompanied in both cases by a significant reduction in the ratio of the 95- and 62-kD isoforms.

In summary, these results support the importance of cAMP in the pathogenesis of PKD, demonstrate the effectiveness in the PCK rat of a VPV2 antagonist to be used in ADPKD clinical trials (OPC-41061), and suggest that OPC-31260 and OPC-41061 inhibit Ras/MAPK signaling in polycystic kidneys.

Acknowledgments

This work was supported by the National Institutes of Health Grant DK44863 (V.E.T.) and research support from Otsuka Pharmaceutical.

References


---

Access to UpToDate on-line is available for additional clinical information at [http://www.jasn.org/](http://www.jasn.org/)